Company Overview and News

 
M Split Corp.: Monthly Dividend Declared for Class I Preferred Shares

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- M Split Corp. ("M Split") declares its monthly distribution of $0.03125 per share ($0.375 annually) for Class I Preferred shareholders. The Class I Preferred share dividends are paid at an annual rate of 7.50% based on the $5 notional issue price. Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018. M Split invests in common shares of Manulife Financial Corporation, the largest life insurer in Canada offering financial products and wealth management services.

 
North American Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (The "Company") declares its regular monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.

 
Dividend 15 Split Corp. Declares 170th Consecutive Monthly Distribution

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. declares its 170th consecutive monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04375 for each Preferred share ($0.525 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.

 
Dividend 15 Split Corp. II Regular Monthly Dividend Declaration for Preferred Share

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. II ("Dividend 15 II") declares its regular monthly distribution of $0.04375 for each Preferred share. Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.

 
Manulife Financial - Overvalued Now, But Still An Opportunity For Growth

2018-05-16 seekingalpha
Most of Manulife's growth has come from their Asia/Pacific segment. This segment will continue to be one of their major focuses going forward.

 
Big 8 Split Inc. Announces Quarterly Dividends on Class D Preferred Shares and Class D Capital Shares

2018-05-11 globenewswire
TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- Big 8 Split Inc. (TSX:BIG.D) (TSX:BIG.pr.D) (the “Company”) announced today that it has declared a quarterly dividend of $0.1125 per Class D Preferred Share. In addition, a quarterly dividend on its Class D Capital Shares was declared of $0.043 per Class D Capital Share. The dividends on both the Class D Preferred Shares and Class D Capital Shares are payable on June 15, 2018 to holders of record on May 31, 2018.

 
Insurers lead Hong Kong stocks higher in morning session

2018-05-08 scmp
Hong Kong stocks began the morning session higher on Tuesday, driven by gains in insurers and overnight advances in Wall Street as investors await a decision by the US to reimpose sanctions on Iran.

 
BRIEF-Manulife Announces Subordinated Green Bond Issue

2018-05-07 reuters
* MANULIFE FINANCIAL CORP - INTENDS TO ISSUE $600 MILLION PRINCIPAL AMOUNT OF 3.317% FIXED/FLOATING SUBORDINATED DEBENTURES DUE MAY 9, 2028

 
CANADA STOCKS - TSX rises, energy sector leads

2018-05-04 reuters
May 4 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 107.93 points, or 0.69 percent, to 15729.4. * The biggest contributor to the TSX gain was Canadian National Railway with 11.68 net index points. Energy was the top sector contributor with 33.38 net points. * Leading the index were Martinrea International Inc, up 10.2 percent, Pason Systems Inc, up 9.4 percent, and Nevsun Resources Ltd, higher by 8.

 
CANADA STOCKS-TSX gains led by financial, energy stocks

2018-05-04 reuters
May 4 (Reuters) - Canada’s main stock index rose on Friday, boosted by the heavy-weight financial sector and energy companies, which were supported by higher oil prices.

 
Manulife Financial's (MFC) CEO Roy Gori on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Please be advised that this conference call is being recorded. Good morning, and welcome to the Manulife Financial's First Quarter 2018 Financial Results Conference Call for Thursday, May 3, 2018. Your host for today will be Mr. Robert Veloso. Please go ahead, sir.

 
Manulife Financial Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-03 seekingalpha
The following slide deck was published by Manulife Financial Corporation in conjunction with their 2018 Q1 earnings call.

 
Manulife (MFC) Q1 Earnings Grow on Strong Segmental Results

2018-05-03 zacks
Manulife Financial Corporation (MFC - Free Report) reported first-quarter 2018 core earnings of $1.03 billion (C$1,303 million), up 22% year over year. This upside stemmed from higher investment-related experience gains in core earnings, strong growth in Asia and Global Wealth and Asset Management, improved policyholder experience in Canada and a favorable impact of lower U.S. tax rates.

 
CANADA STOCKS-TSX flat as materials offset energy losses

2018-05-03 reuters
May 3 (Reuters) - Canada’s main stock index was little changed on Thursday as gains in material and financial stocks were offset by losses in energy shares, which tracked lower oil prices.

 
CANADA STOCKS-TSX opens higher led by gains in materials, financials

2018-05-03 reuters
May 3 (Reuters) - Canada’s main stock index opened slightly higher on Thursday, as precious metals miners gained on higher gold prices, while a rise in Manulife Financial shares boosted the financial sector.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...